These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8200949)

  • 1. Dose-dependent catch-up growth after 2 years of growth hormone treatment in intrauterine growth-retarded children. Belgian and French Pediatric Clinics and Sanofi-Choay (France).
    Chatelain P; Job JC; Blanchard J; Ducret JP; Oliver M; Sagnard L; Vanderschueren-Lodeweyckx M
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1454-60. PubMed ID: 8200949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency.
    Hokken-Koelega AC; Stijnen T; De Jong MC; Donckerwolcke RA; De Muinck Keizer-Schrama SM; Blum WF; Drop SL
    J Clin Endocrinol Metab; 1994 Oct; 79(4):1185-90. PubMed ID: 7525628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial.
    Van Pareren Y; Mulder P; Houdijk M; Jansen M; Reeser M; Hokken-Koelega A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3584-90. PubMed ID: 12915640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
    Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
    Kamp GA; Mul D; Waelkens JJ; Jansen M; Delemarre-van de Waal HA; Verhoeven-Wind L; Frölich M; Oostdijk W; Wit JM
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of beta 1-adrenergic blockade on the growth response to growth hormone (GH)-releasing hormone therapy in GH-deficient children.
    Cassorla F; Mericq V; García H; Cristiano A; Avila A; Boric A; Iñiguez G; Merriam GR
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2997-3001. PubMed ID: 7559887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.
    de Boer H; Blok GJ; Popp-Snijders C; Stuurman L; Baxter RC; van der Veen E
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1371-7. PubMed ID: 8636336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up of three years of treatment with growth hormone and of one post-treatment year, in children with severe growth retardation of intrauterine onset.
    Job JC; Chaussain JL; Job B; Ducret JP; Maes M; Olivier M; Ponte C; Rochiccioli P; Vanderschueren-Lodeweyckx M; Chatelain P
    Pediatr Res; 1996 Feb; 39(2):354-9. PubMed ID: 8825812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose growth hormone treatment of short children born small for gestational age.
    de Zegher F; Maes M; Gargosky SE; Heinrichs C; Du Caju MV; Thiry G; De Schepper J; Craen M; Breysem L; Löfström A; Jönsson P; Bourguignon JP; Malvaux P; Rosenfeld RG
    J Clin Endocrinol Metab; 1996 May; 81(5):1887-92. PubMed ID: 8626853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response study of biosynthetic human growth hormone (GH) in GH-deficient children: effects on auxological and biochemical parameters. Dutch Growth Hormone Working Group.
    de Muinck Keizer-Schrama SM; Rikken B; Wynne HJ; Hokken-Koelega AC; Wit JM; Bot A; Drop SL
    J Clin Endocrinol Metab; 1992 Apr; 74(4):898-905. PubMed ID: 1548357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis.
    de Boer H; Blok GJ; Voerman B; de Vries P; Popp-Snijders C; van der Veen E
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2069-76. PubMed ID: 7608257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. French Serono Study Group.
    Rappaport R; Mugnier E; Limoni C; Crosnier H; Czernichow P; Leger J; Limal JM; Rochiccioli P; Soskin S
    J Clin Endocrinol Metab; 1997 Feb; 82(2):452-6. PubMed ID: 9024235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
    de Zegher F; Du Caju MV; Heinrichs C; Maes M; De Schepper J; Craen M; Vanweser K; Malvaux P; Rosenfeld RG
    J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS.
    Ranke MB; Lindberg A; Albertsson-Wikland K; Wilton P; Price DA; Reiter EO
    J Clin Endocrinol Metab; 2005 Apr; 90(4):1966-71. PubMed ID: 15634724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial.
    Noordam C; Van der Burgt I; Sengers RC; Delemarre-van de Waal HA; Otten BJ
    Acta Paediatr; 2001 Aug; 90(8):889-94. PubMed ID: 11529537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender.
    Johannsson G; Bjarnason R; Bramnert M; Carlsson LM; Degerblad M; Manhem P; Rośen T; Thorén M; Bengtsson BA
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1575-81. PubMed ID: 8636370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant.
    Hokken-Koelega AC; Stijnen T; de Jong RC; Donckerwolcke RA; Groothoff JW; Wolff ED; Blum WF; de Muinck Keizer-Schrama SM; Drop SL
    Kidney Int Suppl; 1996 Jan; 53():S128-34. PubMed ID: 8771007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catch-up growth in autosomal dominant isolated growth hormone deficiency (IGHD type II).
    Binder G; Iliev DI; Mullis PE; Ranke MB
    Growth Horm IGF Res; 2007 Jun; 17(3):242-8. PubMed ID: 17360215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.
    Kriström B; Aronson AS; Dahlgren J; Gustafsson J; Halldin M; Ivarsson SA; Nilsson NO; Svensson J; Tuvemo T; Albertsson-Wikland K
    J Clin Endocrinol Metab; 2009 Feb; 94(2):483-90. PubMed ID: 19001519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial.
    Arends NJ; Boonstra VH; Mulder PG; Odink RJ; Stokvis-Brantsma WH; Rongen-Westerlaken C; Mulder JC; Delemarre-Van de Waal H; Reeser HM; Jansen M; Waelkens JJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):779-87. PubMed ID: 14974922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.